keyword
MENU ▼
Read by QxMD icon Read
search

Varenicline

keyword
https://www.readbyqxmd.com/read/29243347/cost-effectiveness-of-increasing-the-reach-of-smoking-cessation-interventions-in-germany-results-from-the-equiptmod
#1
Manuel B Huber, Maximilian Präger, Kathryn Coyle, Doug Coyle, Adam Lester-George, Marta Trapero-Bertran, Bertalan Nemeth, Kei Long Cheung, Renee Stark, Matthias Vogl, Subhash Pokhrel, Reiner Leidl
AIMS: To evaluate costs, effects and cost-effectiveness of increased reach of specific smoking cessation interventions in Germany. DESIGN: A Markov-based state transition return on investment model (EQUIPTMOD) was used to evaluate current smoking cessation interventions as well as two prospective investment scenarios. A health-care perspective (extended to include out-of-pocket payments) with life-time horizon was considered. A probabilistic analysis was used to assess uncertainty concerning predicted estimates...
December 15, 2017: Addiction
https://www.readbyqxmd.com/read/29236668/-claude-bernard-and-nicotinic-receptors-from-the-neuromuscular-junction-to-tobacco-weaning
#2
Laurent Monassier
Claude Bernard (1813-1878) was fascinated by the pharmacological mechanisms of poisons. In particular, using a huge amount of ingenious and robust experiments, he demonstrated the peripheral toxic action of the natural compound curare. His work generated controversies in a period where scientific methodology and technical development followed the progression of concepts and ideas. From his intense debates with Albert Vulpian emerged the location of curare's toxicity at the neuromuscular junction. These two fascinating scientists could not imagine how important were these discoveries which allowed John Langley to propose the concept of receptor early in the 20th century...
2017: Biologie Aujourd'hui
https://www.readbyqxmd.com/read/29232593/improvement-of-the-association-between-self-reported-pill-count-and-varenicline-levels-following-exclusion-of-participants-with-misreported-pill-count-a-commentary-on-peng-et-al-2017
#3
Annie R Peng, Bernard Le Foll, Mark Morales, Caryn Lerman, Robert Schnoll, Rachel F Tyndale
INTRODUCTION: We previously reported poor associations between salivary varenicline and pill counts, and a substantial overestimation of adherence by pill counts in "Measures and predictors of varenicline adherence in the treatment of nicotine dependence" (Peng et al., 2017). We have since conducted supplementary analyses characterizing, and then excluding, individuals with established inaccurate pill count recall. METHODS: Based on published varenicline pharmacokinetics (including drug levels, and the long half-life) and our detection limits, conservatively we should be able to detect varenicline in anyone who took at least one pill during the 48h prior to saliva collection; thus, those reporting 1 or more pills in this time frame but who had undetectable salivary varenicline were deemed to have inaccurate pill count recall...
December 2, 2017: Addictive Behaviors
https://www.readbyqxmd.com/read/29232312/improvement-of-smoking-abstinence-rates-with-increased-varenicline-dosage-a-propensity-score-matched-analysis
#4
Maher Karam-Hage, George Kypriotakis, Jason D Robinson, Charles E Green, Gurtej Mann, Vance Rabius, Rosario Wippold, Janice A Blalock, Elie Mouhayar, Jean Tayar, Patrick Chaftari, Paul M Cinciripini
PURPOSE/BACKGROUND: It is unclear whether increasing the dose of varenicline beyond the standard dose of 2 mg/d would improve smoking abstinence. METHODS: We examined the effect of 3 mg/d of varenicline on smoking abstinence among smokers who had reduced their smoking by 50% or more in response to 2 mg/d for at least 6 weeks but had not quit smoking. Of 2833 patients treated with varenicline, dosage of a subset of 73 smokers was increased to 3 mg/d after 6 weeks...
December 11, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29226691/could-the-nicotine-receptor-partial-agonist-varenicline-moderate-manic-symptoms-in-heavy-smokers-with-manic-episodes
#5
Ching-Wen Chu, Chin-Han Kao, Chih-Kang Chan
No abstract text is available yet for this article.
December 1, 2017: Australian and New Zealand Journal of Psychiatry
https://www.readbyqxmd.com/read/29223599/pharmacological-intervention-and-abstinence-in-smokers-undergoing-cessation-treatment-a-psychophysiological-study
#6
Yong Cui, Jeffrey M Engelmann, Jonathan Xian, Jennifer A Minnix, Cho Y Lam, Maher Karam-Hage, Paul M Cinciripini, Jason D Robinson
As a composite concept, negative affect comprises various aversive emotional experiences, such as irritability and nervousness. It is a critical motivational factor that helps maintain smoking behavior, and contributes significantly to smoking cessation failure as a core withdrawal symptom. Prior research has indicated an important role of nicotinic mechanisms in negative affect processing. The most effective smoking cessation medication, varenicline, targets nicotinic acetylcholine receptors (nAChRs) as a partial agonist, while another first-line cessation medication, bupropion, has shown antagonistic effects on nAChRs...
December 6, 2017: International Journal of Psychophysiology
https://www.readbyqxmd.com/read/29220524/brain-responses-to-cigarette-related-and-emotional-images-in-smokers-during-smoking-cessation-no-effect-of-varenicline-or-bupropion-on-the-late-positive-potential
#7
Francesco Versace, Elise M Stevens, Jason D Robinson, Yong Cui, Menton M Deweese, Jeffrey M Engelmann, Charles E Green, Maher Karam-Hage, Cho Y Lam, Jennifer A Minnix, David W Wetter, Paul M Cinciripini
Introduction: Varenicline and bupropion are two effective smoking cessation pharmacotherapies. Researchers have hypothesized that they might be effective, in part, because they reduce cue reactivity and cue-induced cravings. Here, we used event-related potentials (ERPs) to directly measure brain responses to cigarette-related and other motivationally relevant images during a pharmacologically aided quit attempt. Methods: Smokers involved in a 12-week placebo-controlled double-blind clinical trial of smoking cessation medications (varenicline, bupropion, placebo) took part in the study...
December 6, 2017: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
https://www.readbyqxmd.com/read/29196725/pharmacogenetic-study-of-seven-polymorphisms-in-three-nicotinic-acetylcholine-receptor-subunits-in-smoking-cessation-therapies
#8
Giulia Pintarelli, Antonella Galvan, Paolo Pozzi, Sara Noci, Giovanna Pasetti, Francesca Sala, Ugo Pastorino, Roberto Boffi, Francesca Colombo
Smoking-cessation therapy reduces the risk of smoking-related diseases, but is successful only in a fraction of smokers. There is growing evidence that genetic variations in nicotinic acetylcholine receptor (nAChR) subunits influence the risk of nicotine dependence and the ability to quit smoking. To investigate the role of polymorphisms in nAChR genes on smoking quantity and the outcome of smoking-cessation therapies, we carried out an association study on 337 smokers who underwent pharmacotherapy with varenicline, bupropion, nicotine replacement therapy (NRT) alone, or NRT plus bupropion...
December 1, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29180549/family-physicians-perceived-prevalence-safety-and-screening-for-cigarettes-marijuana-and-electronic-nicotine-delivery-systems-ends-use-during-pregnancy
#9
Thomas F Northrup, Michelle R Klawans, Yolanda R Villarreal, Adi Abramovici, Melissa A Suter, Joan M Mastrobattista, Carlos A Moreno, Kjersti M Aagaard, Angela L Stotts
OBJECTIVE: Assess perceptions of prevalence, safety, and screening practices for cigarettes and secondhand smoke exposure (SHSe), marijuana (and synthetic marijuana), electronic nicotine delivery systems (ENDS; eg, e-cigarettes), nicotine-replacement therapy (NRT), and smoking-cessation medications during pregnancy, among primary care physicians (PCPs) providing obstetric care. METHODS: A web-based, cross-sectional survey was e-mailed to 3750 US physicians (belonging to organizations within the Council of Academic Family Medicine Educational Research Alliance)...
November 2017: Journal of the American Board of Family Medicine: JABFM
https://www.readbyqxmd.com/read/29179044/nicotine-as-a-discriminative-stimulus-for-ethanol-use
#10
Brett C Ginsburg, Simon A Levy, R J Lamb
Abused drugs reinforce behavior; i.e., they increase the probability of the behavior preceding their administration. Abused drugs can also act as discriminative stimuli; i.e., they can set the occasion for responding reinforced by another event. Thus, one abused drug could come to set the occasion for the use of another and this functional relationship may play a role in polysubstance abuse, where common patterns of use could result in this relationship. Here we establish nicotine (0.4mg/kg, ip 5-min pre-session) as a discriminative stimulus for behavior reinforced by ethanol (0...
November 21, 2017: Drug and Alcohol Dependence
https://www.readbyqxmd.com/read/29168193/the-effects-of-long-term-varenicline-administration-on-ethanol-and-sucrose-seeking-and-self-administration-in-male-p-rats
#11
Cristine L Czachowski, Janice C Froehlich, Michael DeLory
BACKGROUND: Varenicline, a partial agonist at α4β2 and full agonist at α7 nicotinic cholinergic receptors, is FDA approved for treatment of smoking cessation and has been found to reduce alcohol craving in clinical populations. In rodents, varenicline decreases free-choice ethanol intake with somewhat mixed findings in operant paradigms that utilize a combined appetitive/consummatory response. METHODS: The present experiment utilized an operant paradigm that procedurally separates appetitive from consummatory responding and a "reward blocking" approach (i...
November 23, 2017: Alcoholism, Clinical and Experimental Research
https://www.readbyqxmd.com/read/29150536/availability-sales-and-affordability-of-tobacco-cessation-medicines-in-kerala-india
#12
Smitha Sarma, Sivadasanpillai Harikrishnan, Abigail S Baldridge, Raji Devarajan, Aashna Mehta, Sakhtivel Selvaraj, Mohammed K Ali, Padinhare P Mohanan, Dorairaj Prabhakaran, Mark D Huffman
BACKGROUND: India is the world's second largest consumer of tobacco, but tobacco cessation remains uncommon due, at least in part, to underutilization of cessation pharmacotherapy. We evaluated the availability, sales, and affordability of nicotine replacement therapy, bupropion, and varenicline in the South Indian state of Kerala to understand potential reasons for underutilization. METHODS AND RESULTS: From November 2016 to April 2017, we collected data on availability, inventory, and pricing of cessation medication through a cross-sectional survey of 199 public, semiprivate (Karunya), and private pharmacies across 5 districts in Kerala using World Health Organization/Health Action International methodology...
November 2017: Circulation. Cardiovascular Quality and Outcomes
https://www.readbyqxmd.com/read/29133020/-the-fight-against-smoking-the-need-to-consider-behavioral-dependence
#13
REVIEW
C Guillaumin, T Urban
The prevalence of smoking in France remains very high compared to other developed Western countries. The management of smoking in smokers is often limited to nicotinic substitution, whether medicated or linked to the use of electronic cigarettes or varenicline and advices more or less reliable or helpful. This strategy of aiding smoking cessation, if isolated, leads to a high number of failures. It is therefore necessary to consider behavioral dependence, in the broad sense in three aspects, "behavioral" (the motor Gestures), cognitive (thoughts) and emotional (emotions)...
November 10, 2017: Revue de Pneumologie Clinique
https://www.readbyqxmd.com/read/29117796/effects-of-varenicline-therapy-in-combination-with-advanced-behavioral-support-on-smoking-cessation-and-quality-of-life-in-inpatients-with-acute-exacerbation-of-copd-bronchial-asthma-or-community-acquired-pneumonia-a-prospective-open-label-preference-based
#14
Alexios Politis, Vasileios Ioannidis, Konstantinos I Gourgoulianis, Zoe Daniil, Chrissi Hatzoglou
Quitting smoking is the most important element in the therapeutic management of chronic respiratory diseases. Combining pharmacotherapy with behavioral support increases smoking cessation success rates. In addition, hospitalized smokers have increased motivation to quit. We investigated the efficacy on smoking cessation, of varenicline in combination with behavioral support, in smokers hospitalized due to (a) acute exacerbation of chronic obstructive pulmonary disease (COPD), or (b) bronchial asthma attack, or (c) community-acquired pneumonia (CAP)...
January 1, 2017: Chronic Respiratory Disease
https://www.readbyqxmd.com/read/29075117/need-for-medication-to-complement-catecholamines-in-smoking-cessation-of-hardcore-smokers
#15
Atsuko Kawai, Masatake Kurita, Satoshi Nishino, Eishin Hirata, Tadahiro Sato, Yoshiro Okubo
Many smokers find it difficult to stop smoking without assistance. The antidepressants bupropion and nortriptyline can aid smoking cessation. The main aim of this study was to understand the pathophysiology of smoking cessation better based on biological backgrounds. We investigated the following biological markers for any alterations during smoking cessation in the absence of pharmacotherapy: the dopamine metabolite homovanillic acid (HVA), the noradrenaline metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) and brain-derived neurotrophic factor (BDNF)...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29064842/effect-of-varenicline-on-behavioral-deficits-in-a-rat-model-of-parkinson-s-disease-induced-by-unilateral-6-hydroxydopamine-lesion-of-substantia-nigra
#16
Rüyal Tan, Funda Bölükbaşi Hatip, Öznur Açikalin, Atsushi Yamauchi, Yasufumi Kataoka, Izzettin Hatip-Al-Khatib
Nicotinic acetylcholine receptors (nAChRs) are implicated in the pathogenesis of Parkinson's disease (PD). Varenicline tartrate is a partial agonist at α4β2 and full agonist at α7 neuronal nAChR subunits. A unilateral lesion of the substantia nigra (SN) has been used as a reliable model of PD. This study aimed to investigate the effect of varenicline on locomotor and nonlocomotor behavioral deficits induced by a unilateral lesion of the SN induced by 6-hydroxydopamine (6-OHDA) (8 µg/4 µl). Varenicline (1 mg/kg) was administered to the lesioned rats daily for 2 weeks, which commenced 3 weeks after 6-OHDA administration...
October 23, 2017: Behavioural Pharmacology
https://www.readbyqxmd.com/read/29059422/reversal-of-nicotine-withdrawal-signs-through-positive-allosteric-modulation-of-%C3%AE-4%C3%AE-2-nicotinic-acetylcholine-receptors-in-male-mice
#17
Ayman K Hamouda, Asti Jackson, Deniz Bagdas, M Imad Damaj
Introduction: Nicotine withdrawal symptoms are important factors in determining the relapse rate to tobacco smoking and drugs that diminish these symptoms would potentially have a higher success rate as smoking cessation aids. Unlike FDA-approved smoke cessation aids (nicotine and varenicline) which act as nicotinic acetylcholine receptors (nAChRs) agonists, desformylflustrabromine (dFBr) acts as a nAChR positive allosteric modulator with higher selectivity to the α4β2 nAChR. In animal studies, dFBr was well tolerated and reduced intravenous nicotine self-administration...
August 18, 2017: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
https://www.readbyqxmd.com/read/29059409/facilitated-extinction-training-to-improve-pharmacotherapy-for-smoking-cessation-a-pilot-feasibility-trial
#18
Thomas H Brandon, Marina Unrod, David J Drobes, Steven K Sutton, Larry W Hawk, Vani N Simmons, Karen O Brandon, Richard G Roetzheim, Lauren R Meltzer, Ralph R Miller, Shawn P Cahill
Introduction: Varenicline reduces smoking satisfaction during the pre-cessation run-in period, which may contribute to extinction of cravings and smoking behavior. Research indicates that efficacy is enhanced when the run-in period is increased from 1 to 4 weeks, providing a longer extinction opportunity. We hypothesized that efficacy could be further enhanced by harnessing basic and applied research on extinction. We developed a pre-cessation extinction-facilitating intervention and tested its feasibility in a pilot trial...
September 12, 2017: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
https://www.readbyqxmd.com/read/29059367/nicotine-metabolism-informed-care-for-smoking-cessation-a-pilot-precision-rct
#19
Quinn S Wells, Matthew S Freiberg, Robert A Greevy, Rachel F Tyndale, Suman Kundu, Meredith S Duncan, Stephen King, Elizabeth Scoville, Dawn Beaulieu, Vanessa Gatskie, Hilary A Tindle
Introduction: Varenicline doubles cessation over nicotine replacement therapy (NRT) patch for "normal," but not "slow," nicotine metabolizers, as assessed by the nicotine metabolite ratio (NMR). Metabolism-informed care (MIC) could improve outcomes by matching normal metabolizers with non-nicotine medication (e.g., varenicline) and slow metabolizers with NRT patch. Methods: We conducted a feasibility randomized controlled trial of MIC vs. guideline based care (GBC) among 81 outpatient adult daily smokers with medical comorbidity...
October 14, 2017: Nicotine & Tobacco Research: Official Journal of the Society for Research on Nicotine and Tobacco
https://www.readbyqxmd.com/read/29058146/human-nicotinic-receptors-in-chromaffin-cells-characterization-and-pharmacology
#20
REVIEW
Almudena Albillos, J Michael McIntosh
During the last 10 years, we have been working on human chromaffin cells obtained from the adrenal gland of organ donors that suffered encephalic or cardiac death. We first electrophysiologically characterized the nicotinic acetylcholine receptors (nAChRs) activated by acetylcholine, and their contribution to the exocytosis of chromaffin vesicles and release of catecholamines. We have shown that these cells possess an adrenergic phenotype. This phenotype may contribute to an increased expression of α7 nAChRs in these cells, allowing for recording of α7 nAChR currents, something that had previously not been achieved in non-human species...
October 20, 2017: Pflügers Archiv: European Journal of Physiology
keyword
keyword
77072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"